Opinion

Video

Myths Surrounding Liquid Biopsy and ctDNA Testing for MRD

Author(s):

John L. Marshall, MD,Benjamin Weinberg, MD

Pashtoon Murtaza Kasi, MD, MS, emphasizes key aspects of liquid biopsy and ctDNA testing in the MRD treatment landscape.

Related Videos
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
5 KOLs are featured in this series.
Related Content
Sebastian Kaulitzki – stock.adobe.com
November 15th 2024

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
October 24th 2024

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

Oncology Unplugged
August 21st 2024

Park and Kasi Expand on Perioperative Immunotherapy Updates in CRC

Thomas J. Lynch Jr., MD
November 5th 2024

Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology